Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study

Brain Tumors

(2015) Murali Chintagumpala et al.   PEDIATRIC CLINICS OF NORTH AMERICA

Targeting p53 for Novel Anticancer Therapy

(2014) Zhen Wang et al.   Translational Oncology

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

(2013) M A Warso et al.   BRITISH JOURNAL OF CANCER

p28, A first in class peptide inhibitor of cop1 binding to p53

(2013) T Yamada et al.   BRITISH JOURNAL OF CANCER

p28, an Anionic Cell-Penetrating Peptide, Increases the Activity of Wild Type and Mutated p53 without Altering Its Conformation

(2013) Tohru Yamada et al.   MOLECULAR PHARMACEUTICS

Integrin  5 1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma

(2012) H. Janouskova et al.   CANCER RESEARCH

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

(2012) Trevor J. Pugh et al.   NATURE

Novel mutations target distinct subgroups of medulloblastoma

(2012) Giles Robinson et al.   NATURE

Dissecting the genomic complexity underlying medulloblastoma

(2012) David T. W. Jones et al.   NATURE

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

(2012) Paul A. Northcott et al.   NATURE

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt

(2011) Rajeshwari R. Mehta et al.   ANGIOGENESIS

Glioma Models: New GEMMs Add “Class” with Genomic and Expression Correlations

(2011) Cécile L. Maire et al.   CANCER CELL

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination

(2010) Lee Jia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease

(2010) Barbara S. Paugh et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice

(2010) Greg S. Gorman et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

HDMX regulates p53 activity and confers chemoresistance to 3-Bis(2-chloroethyl)-1-nitrosourea

(2010) Genglin Jin et al.   NEURO-ONCOLOGY

Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells

(2009) B. N. Taylor et al.   CANCER RESEARCH

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells

(2009) T. Yamada et al.   MOLECULAR CANCER THERAPEUTICS